XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.92

+0.2%

Feb 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (11369)	8/18/1999 11:42:00 AM
From: aknahow	Read Replies (2) of 17367

Does not quite work that way. The concession is getting a regulatory agency to even agree to look at more. No one in any agency is going to say submission of more data will increase your potential for approval. If you had a turn down on the preliminary and were somehow then able to get a regulator to look at additional information, the potential has increased but that is only because before you had been turned down. Now you have a slim chance the agency might change its mind. But of course even less than a zero chance that the agency will say their looking at the additional data signifies anything. This post is based on experience in dealing with another Federal Regulator not the FDA but the logic applies and what you are asking about or proposing is not even remotely possible.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next